Simon joined Advent in 2017 and brings almost 30 years of senior commercial leadership experience at life-science companies in the UK and mainland Europe.
Simon is currently the CEO of Advent portfolio company, Curve Therapeutics Limited, which was established in 2019 to develop and commercialise a powerful drug discovery platform. Prior to Curve, Simon supported a number of early-stage Advent companies.
Prior to joining Advent, Simon was CEO of Karus Therapeutics, a cancer drug discovery and development company and, before that, he led the Business Development team at Ablynx, where he secured a number of pharma partnerships. Prior to Ablynx, Simon held senior BD positions at Active Biotech, Isogenica (which he co-founded) and Actinova.
Simon is a medicinal chemist by background, gaining a PhD from Loughborough University (1989) and an Executive MBA (1995) from Loughborough University Business School.